Shamburg News · 8-K filed Nov 12, 2026, 8:01 AM EST

Grace Therapeutics Reports Q2 2027 Net Loss of $2.1 Million and Updates on GTx-104 NDA

GRCE · Grace Therapeutics, Inc.

  • Earnings
  • Materiality: high

Grace Therapeutics, Inc. reported a net loss of $2.1 million, or $0.11 per share, for the three months ended September 30, 2026, compared with a net loss of $0.9 million, or $0.06 per share, for the same period a year earlier. Cash and cash equivalents were $21.3 million at September 30, 2026, and the Company said its existing cash is expected to fund planned operations through the end of calendar 2028, following a private placement with net proceeds of $9.2 million. The Company also reported progress on a dual-source manufacturing strategy for GTx-104 and on the FDA meeting minutes related to the Complete Response Letter.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001140361-26-043308.

Written from the filing by Shamburg Markets. Figures are as reported by the company.